多中心住院肝硬化队列中入院血清代谢物与甲状腺素预测晚期肝性脑病
多中心前瞻性住院肝硬化队列纳入602例无脑衰竭患者,144例在入院3天后发生脑衰竭;随机森林分析显示入院时较高微生物来源代谢物及较低异亮氨酸、甲状腺素和溶血磷脂与脑衰竭发生相关(AUC 0.87,仅脑衰竭0.90)。仅用临床变量的逻辑回归模型加入代谢物后AUC显著改善(95%CI 0.65-0.75;P=0.005)。在81例前瞻性验证队列中11例发生脑衰竭,入院医院实验室甲状腺素水平在控制临床变量后仍以高特异性预测脑衰竭发生。
要点
- 入院血清代谢物谱可预测肝硬化患者晚期肝性脑病(脑衰竭)发生,随机森林AUC 0.87。
- 仅用临床变量的模型加入代谢物后预测能力显著改善(P=0.005)。
- 入院医院实验室甲状腺素水平在独立验证队列中可高特异性预测脑衰竭发生。
核心结论
- 在多中心住院队列中,入院血清代谢物(包括甲状腺素)独立于临床因素预测晚期肝性脑病发生。
- 入院当地实验室低甲状腺素水平在独立队列中被验证为晚期肝性脑病发生的预测因素。
研究设计与样本
- 前瞻性住院肝硬化队列(多中心及两中心验证),无脑衰竭患者入院时采集血清并进行住院期间随访评估。
- 多中心队列纳入602例患者。
- 另招募独立验证队列,纳入81例前瞻性入组患者。
- 采用随机森林分析和逻辑回归分析血清代谢组学以预测脑衰竭。
主要发现
- 多中心队列602例中144例在入院3天后发生脑衰竭,其中105例仅发生脑衰竭。
- 未校正随机森林分析显示,入院时较高微生物来源代谢物及较低异亮氨酸、甲状腺素和溶血磷脂与脑衰竭发生相关(AUC 0.87;仅脑衰竭AUC 0.90)。
- 仅用临床变量的逻辑回归模型AUC加入代谢物后显著改善(95%CI 0.65-0.75;P=0.005)。
- 对脑衰竭预测有显著额外贡献的四种代谢物为低甲状腺素和麦芽糖、高甲基-4-羟基苯甲酸硫酸盐和3-4二羟基丁酸。
- 甲状腺素单独加入模型亦显著改善预测(P=0.05)。
关键数值与推荐
- 多中心队列脑衰竭发生率:144/602例(105例仅脑衰竭)于入院3天后发生。
- 随机森林预测脑衰竭AUC 0.87,仅脑衰竭AUC 0.90。
- 仅临床变量逻辑回归模型加入代谢物后AUC的95%CI为0.65-0.75,P=0.005。
- 四种代谢物显著增加脑衰竭预测:低甲状腺素、低麦芽糖、高甲基-4-羟基苯甲酸硫酸盐、高3-4二羟基丁酸。
- 甲状腺素单独加入模型P=0.05。
临床怎么用
- 入院血清代谢物(包括甲状腺素)可用于预测住院肝硬化患者晚期肝性脑病发生,独立于临床因素。
- 入院当地实验室甲状腺素水平可在独立队列中高特异性预测脑衰竭发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Grades 3 to 4 hepatic encephalopathy (advanced HE), also termed brain failure, is an organ failure that defines acute-on-chronic liver failure. It is associated with poor outcomes in cirrhosis but cannot be predicted accurately. We aimed to determine the admission metabolomic biomarkers able to predict the development of advanced HE with subsequent validation. METHODS: Prospective inpatient cirrhosis cohorts (multicenter and 2-center validation) without brain failure underwent admission serum collection and inpatient follow-up evaluation. Serum metabolomics were analyzed to predict brain failure on random forest analysis and logistic regression. A separate validation cohort also was recruited. RESULTS: The multicenter cohort included 602 patients, of whom 144 developed brain failure (105 only brain failure) 3 days after admission. Unadjusted random forest analysis showed that higher admission microbially derived metabolites and lower isoleucine, thyroxine, and lysophospholipids were associated with brain failure development (area under the curve, 0.87 all; 0.90 brain failure only). Logistic regression area under the curve with only clinical variables significantly improved with metabolites (95% CI 0.65-0.75; P = .005). Four metabolites that significantly added to brain failure prediction were low thyroxine and maltose and high methyl-4-hydroxybenzoate sulfate and 3-4 dihydroxy butyrate. Thyroxine alone also significantly added to the model (P = .05). The validation cohort including 81 prospectively enrolled patients, of whom 11 developed brain failure. Admission hospital laboratory thyroxine levels predicted brain failure development despite controlling for clinical variables with high specificity. CONCLUSIONS: In a multicenter inpatient cohort, admission serum metabolites, including thyroxine, predicted advanced HE development independent of clinical factors. Admission low local laboratory thyroxine levels were validated as a predictor of advanced HE development in a separate cohort.
引用
- Bajaj JS, Tandon P, O'Leary JG, et al. Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2022. PMID: 35436625. doi:10.1016/j.cgh.2022.03.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。